Skip to content
Screener

Glaukos GKOS Total Liabilities

Total Liabilities at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$116.09B+1.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$10.02B+21.0%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$51.98M0.0%
Schering-Plough logo
Schering-PloughSGP
$8.27M
Bausch + Lomb logo
Bausch + LombBLCO
$7.42B+1.2%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$150.96M+7.8%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.09B+98.7%
Enterprise value$10.08B+98.3%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemJune 30, 2026December 31, 2025
Finance lease liability67,34568,109
Deferred tax liability, net441441
Other liabilities32,42931,740
Total liabilities238,035237,332
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding as of June 30, 2026 and December 31, 2025--
Common stock, $0.001 par value; 150,000 shares authorized; 58,886 and 57,539 shares issued and 58,858 and 57,511 shares outstanding as of June 30, 2026 and December 31, 2025, respectively5958

Item 1. Financial Statements

FAQ

What is Glaukos's total liabilities?
Glaukos (GKOS) reported total liabilities of $238.04M in Q2 2026.
How has Glaukos's total liabilities changed year-over-year?
Glaukos's total liabilities increased by 7.3% year-over-year, from $221.85M to $238.04M.
What is the long-term trend for Glaukos's total liabilities?
Over 5 years (2020 to 2025), Glaukos's total liabilities has grown at a -6.8% compound annual growth rate (CAGR), from $338.05M to $237.33M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Glaukos's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude